Indivior wary of rivals launching copycat products after US court denies appeal to keep ban in place


Indivior said Tuesday a U.S. court had denied its appeal against a decision that would lift the ban preventing rival Dr. Reddy's Laboratories from selling a generic version of the company's opioid addiction treatment.

Indivior said it would file an emergency request to keep the ban in place pending resolution of its forthcoming application for an administrative stay to the Supreme Court of the United States.

The U.S. Court of Appeals for the Federal Circuit had denied Indivior's appeal on February 11, and ordered that the rival Dr. Reddy's Laboratories be granted the right to sell a generic version of the company's opioid treatment on February 19, 2019.

'After the mandate issues, Dr. Reddy's Laboratories and Alvogen Pine Brook will no longer be prevented from selling, offering to sell, or importing their generic buprenorphine/naloxone sublingual film product,' Indivior said.

Related content

Broker Forecast - Jefferies International issues a broker note on Indivior Plc

Jefferies International today reaffirms its hold investment rating on Indivior Plc (LON:INDV) and cut its price target to 39p (from 65p).

Broker Forecasts data provided...

Tue, 21/01/2020 - 10:40

FTSE opens up 0.1% as investors eye crucial Brexit, US-China trade talks

UK stocks opened modestly higher on Tuesday as investors braced for the outcome of crucial Brexit and US-China trade negotiations taking place separately this week....

Tue, 15/10/2019 - 08:53

Indivior upgrades profit outlook on stronger-than-expected performance of opioid addiction drug

Drug company Indivior upgraded its full-year profit outlook following stronger-than-expected net revenue performance as sales of its opioid addiction treatment had fared better than expected...

Tue, 15/10/2019 - 08:02

Indivior profits rises in Q2 as opioid addiction treatment fares better than expected

Drugmaker Indivior reported a rise in profits on stronger-than-expected second-quarter performance, during which its opioid-addiction treatment loss less market share than expected following the launch...

Wed, 31/07/2019 - 09:53

Reckitt and Indivior soar on US settlement and shares in housebuilders lifted by property market data

“UK and Asian stocks followed the upwards trend seen last night in the US after the Fed signalled an interest rate cut. The FTSE 100...

Thu, 11/07/2019 - 11:20